TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Roth Capital

Roth Capital upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports. Roth Capital also issued estimates for TriSalus Life Sciences’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.47) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.19) EPS.

A number of other equities analysts have also recently commented on TLSI. Oppenheimer assumed coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Roth Mkm initiated coverage on TriSalus Life Sciences in a report on Monday. They set a “buy” rating and a $11.00 price target for the company. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus target price of $12.25.

TriSalus Life Sciences Trading Up 0.9 %

NASDAQ:TLSI opened at $4.50 on Monday. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42. The stock has a fifty day moving average price of $4.39 and a 200-day moving average price of $5.86.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $7.36 million during the quarter. Analysts expect that TriSalus Life Sciences will post -1.5 earnings per share for the current year.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the transaction, the chief executive officer now directly owns 377,382 shares in the company, valued at approximately $1,962,386.40. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 32.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLSI. Highbridge Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth approximately $1,184,000. Duquesne Family Office LLC raised its stake in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the last quarter. Finally, Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth approximately $240,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.